menu
    • menu
    [{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Rislenemdaz","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Neurology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Cerecor"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NFC-1","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"NFC-1","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aevi Genomic Medicine \/ Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment","highestDevelopmentStatusID":"9","companyTruncated":"Aevi Genomic Medicine \/ Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NFC-1","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NFC-1","moa":"mGluR5","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fasoracetam","moa":"nootropes (piracetam type)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fasoracetam","moa":"nootropes (piracetam type)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CERC-002","moa":"Tumor necrosis factor ligand superfamily member 14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Medgenics Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"MDGN201","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Medgenics Medical","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Medgenics Medical"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Medgenics Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"MDGN201","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Medgenics Medical","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Medgenics Medical"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Medgenics Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"MDGN201","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Medgenics Medical","highestDevelopmentStatusID":"7","companyTruncated":"Aevi Genomic Medicine \/ Medgenics Medical"}]

    Find Clinical Drug Pipeline Developments & Deals by Aevi Genomic Medicine

    Menu

    Aevi Genomic Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CERC-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

                            Details : CERC-002 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 02, 2020

                            Lead Product(s) : CERC-002

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rislenemdaz

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Cerecor

                            Deal Size : $22.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cerecor and Aevi Genomic Medicine Complete Merger

                            Details : Cerecor’s pipeline now includes six clinical-stage assets, accelerating the company’s transformation into a research organization focused on developing new medicines for unmet needs in rare diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 03, 2020

                            Lead Product(s) : Rislenemdaz

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Cerecor

                            Deal Size : $22.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasoracetam

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

                            Details : AEVI-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2018

                            Lead Product(s) : Fasoracetam

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fasoracetam

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

                            Details : AEVI-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 29, 2017

                            Lead Product(s) : Fasoracetam

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NFC-1

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

                            Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 30, 2016

                            Lead Product(s) : NFC-1

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NFC-1

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric C...

                            Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of DiGeorge Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 12, 2016

                            Lead Product(s) : NFC-1

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NFC-1

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

                            Details : NFC-1 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 19, 2016

                            Lead Product(s) : NFC-1

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDGN201

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Medgenics Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TARGTEPO Treatment for Anemia in PD US Trial

                            Details : MDGN201 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia-associated with Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 10, 2015

                            Lead Product(s) : MDGN201

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Medgenics Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDGN201

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Medgenics Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)

                            Details : MDGN201 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia-associated with Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 04, 2015

                            Lead Product(s) : MDGN201

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Medgenics Medical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Aevi Genomic Medicine

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NFC-1

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Stu...

                            Details : NFC-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 10, 2014

                            Lead Product(s) : NFC-1

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Thomas Jefferson University | Children's Hospital of Philadelphia | Pearson Clinical Assessment

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth